PE57198A1 - Formula de liberacion prolongada - Google Patents

Formula de liberacion prolongada

Info

Publication number
PE57198A1
PE57198A1 PE00015497A PE00015497A PE57198A1 PE 57198 A1 PE57198 A1 PE 57198A1 PE 00015497 A PE00015497 A PE 00015497A PE 00015497 A PE00015497 A PE 00015497A PE 57198 A1 PE57198 A1 PE 57198A1
Authority
PE
Peru
Prior art keywords
weight
composition
content
propil
spheroids
Prior art date
Application number
PE00015497A
Other languages
English (en)
Inventor
Marie Sherman Deborah
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21762972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE57198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of PE57198A1 publication Critical patent/PE57198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

SE REFIERE A LA COMPOSICION DE LOS ESFEROIDES, QUE COMPRENDE: a) 37,3% EN PESO DE CLORHIDRATO DE VENLAFAXINA; b) ALREDEDOR DEL 62,17 % EN PESO DE CELULOSA MICROCRISTALINA; c) ALREDEDOR DEL 0,5% EN PESO DE HIDROXI-PROPIL-METILCELULOSA 2208; d) UNA PELICULA DE RECUBRIMIENTO. TAMBIEN SE REFIERE A LA COMPOSICION DE UNA PELICULA DE RECUBRIMIENTO, QUE COMPRENDE: i) 85% DEL PESO TOTAL DE ETILCELULOSA, CON UN CONTENIDO DE GRUPOS ETOXI DEL 44% AL 51%; ii) 15% DEL PESO TOTAL DE HIDROXI-PROPIL-METILCELULOSA, CON UN CONTENIDO DE METOXI DEL 28% AL 30% Y UN CONTENIDO DE GRUPOS HIDROXI PROPOXI DEL 7% AL 12%. EN ESTA COMPOSICION, LOS ESFEROIDES SE ENCUENTRAN CONTENIDOS EN UNA CAPSULA DE GELATINA, Y SE MANTIENEN EN UNA CONCENTRACION SERICA TERAPEUTICA DURANTE UN PERIODO DE 24 HORAS, REDUCIENDOSE, ASI, LOS EFECTOS SECUNDARIOS (NAUSEAS Y EMESIS) DEL ANTIDEPRESIVO CLORHIDRATO DE 1-[2-(DIMETILAMINO)-1-(4-METOXIFENIL)ETIL]CICLOHEXANOL
PE00015497A 1996-03-25 1997-03-04 Formula de liberacion prolongada PE57198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1400696P 1996-03-25 1996-03-25

Publications (1)

Publication Number Publication Date
PE57198A1 true PE57198A1 (es) 1998-10-10

Family

ID=21762972

Family Applications (1)

Application Number Title Priority Date Filing Date
PE00015497A PE57198A1 (es) 1996-03-25 1997-03-04 Formula de liberacion prolongada

Country Status (34)

Country Link
EP (2) EP0797991B1 (es)
JP (2) JP4771565B2 (es)
KR (1) KR101096512B1 (es)
CN (2) CN1090018C (es)
AR (1) AR006519A1 (es)
AT (1) ATE257011T1 (es)
AU (1) AU727653B2 (es)
BR (1) BR9701304A (es)
CA (1) CA2199778C (es)
CO (1) CO4761054A1 (es)
CY (1) CY2442B1 (es)
CZ (1) CZ291637B6 (es)
DE (1) DE69727000T2 (es)
DK (1) DK0797991T3 (es)
EG (1) EG24198A (es)
ES (1) ES2210454T3 (es)
HK (1) HK1056686A1 (es)
HU (1) HU224617B1 (es)
IL (1) IL120382A (es)
IN (1) IN187337B (es)
NO (2) NO320355B1 (es)
NZ (1) NZ314442A (es)
PA (1) PA8426401A1 (es)
PE (1) PE57198A1 (es)
PL (2) PL195564B1 (es)
PT (1) PT797991E (es)
RU (1) RU2176912C2 (es)
SK (1) SK281530B6 (es)
SV (1) SV1997000015A (es)
TR (1) TR199700190A2 (es)
TW (1) TW493993B (es)
UA (1) UA44904C2 (es)
UY (1) UY24613A1 (es)
ZA (1) ZA972403B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
JP3379461B2 (ja) * 1998-08-06 2003-02-24 三菱電機株式会社 コア部材の積層金型装置、コア部材の積層方法および電動機
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
CA2374039C (en) * 1999-05-20 2011-01-11 Elan Corporation Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
AU2002241764A1 (en) * 2000-10-19 2002-06-18 Teva Pharmaceutical Industries Ltd. Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
SE0102886D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
SE0102888D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
HUP0104872A3 (en) * 2001-11-13 2004-04-28 Egis Gyogyszergyar Nyilvanosan New polymorphic forms of venlafaxine, process for their preparation, pharmaceutical compositions containing them and their use
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
AR039164A1 (es) 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
WO2004069228A2 (en) * 2003-02-07 2004-08-19 Omega Farma Ehf. Sustained release formulations of venlafaxine
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
PT1473030E (pt) 2003-05-02 2007-01-31 Dexcel Ltd Formulação para um comprimido de libertação prolongada de venlafaxina
IN2003MU00504A (es) * 2003-06-05 2005-05-13 Alembic Ltd
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
SI1502587T1 (sl) 2003-07-30 2007-02-28 Pharmathen Sa Formulacija z zadrzevanim sproscanjem za Venlafaxin hidroklorid
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1523979A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release pharmaceutical dosage form
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
DE10359154A1 (de) 2003-12-16 2005-07-28 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
SI1711169T1 (sl) 2004-02-04 2007-10-31 Alembic Ltd Obložene minitablete venlafaksin hidroklorida s podaljšanim sproščanjem
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100463676C (zh) * 2004-11-11 2009-02-25 成都康弘药业集团股份有限公司 一种盐酸文拉法辛控释片制剂及其制备方法
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) * 2006-04-03 2014-04-02 オディディ，イサ オルガノゾル被膜を含む制御放出送達デバイス
PL2010158T3 (pl) 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
KR100791194B1 (ko) * 2006-06-12 2008-01-02 코오롱제약주식회사 염산 벤라팍신의 경구 투여용 서방성 펠렛 및 그 제조방법
HUE044221T2 (hu) * 2010-02-03 2019-10-28 Pharma Two B Ltd Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
CA2826180C (en) 2011-01-31 2020-09-01 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
IE60311B1 (en) 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
ES2174864T3 (es) * 1993-06-28 2002-11-16 Wyeth Corp Nuevos tratamientos que utilizan derivados de fenetilo.
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada

Also Published As

Publication number Publication date
DE69727000T2 (de) 2004-06-09
PL188444B1 (pl) 2005-02-28
SK30197A3 (en) 1997-10-08
NO971206D0 (no) 1997-03-14
AU727653B2 (en) 2000-12-21
TR199700190A2 (xx) 1997-10-21
HUP9700589A2 (en) 1997-09-29
CA2199778A1 (en) 1997-09-25
MX9701873A (es) 1997-09-30
IN187337B (es) 2002-03-30
HUP9700589A3 (en) 2001-03-28
DK0797991T3 (da) 2004-04-05
JP2008156374A (ja) 2008-07-10
AR006519A1 (es) 1999-09-08
CY2442B1 (en) 2004-11-12
PT797991E (pt) 2004-05-31
PL195564B1 (pl) 2007-10-31
UA44904C2 (uk) 2002-03-15
CZ291637B6 (cs) 2003-04-16
AU1640097A (en) 1997-10-02
HU224617B1 (hu) 2005-11-28
CA2199778C (en) 2005-12-20
HU9700589D0 (en) 1997-05-28
UY24613A1 (es) 2000-09-29
JP4771565B2 (ja) 2011-09-14
EP2881110A1 (en) 2015-06-10
CN1164389A (zh) 1997-11-12
KR101096512B1 (ko) 2014-11-28
PL318954A1 (en) 1997-09-29
CN1090018C (zh) 2002-09-04
NO971206L (no) 1997-09-26
KR970064599A (ko) 1997-10-13
JPH107552A (ja) 1998-01-13
CZ77297A3 (en) 1997-11-12
NO320355B1 (no) 2005-11-28
CN1403077A (zh) 2003-03-19
IL120382A (en) 2003-06-24
BR9701304A (pt) 1998-09-29
NZ314442A (en) 1999-06-29
PA8426401A1 (es) 2000-05-24
SV1997000015A (es) 1997-08-13
DE69727000D1 (de) 2004-02-05
NO20050379L (no) 1997-09-26
SK281530B6 (sk) 2001-04-09
EP0797991B1 (en) 2004-01-02
EG24198A (en) 2008-10-14
EP0797991A1 (en) 1997-10-01
RU2176912C2 (ru) 2001-12-20
ATE257011T1 (de) 2004-01-15
ZA972403B (en) 1998-09-21
TW493993B (en) 2002-07-11
ES2210454T3 (es) 2004-07-01
CO4761054A1 (es) 1999-04-27
HK1056686A1 (en) 2004-02-27
IL120382A0 (en) 1997-07-13

Similar Documents

Publication Publication Date Title
PE57198A1 (es) Formula de liberacion prolongada
YU47204B (sh) Derivati didehidro-vitamina d3
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
DK0796082T3 (da) Orale sammensætninger indeholdende stabiliserede tinforbindelser
ES2110747T3 (es) Composicion cosmetica que contiene precursores de ceramida.
ES2095446T3 (es) Una protesis de valvula cardiaca, en particular para sustituir la valvula aortica.
PE128699A1 (es) Formula de liberacion prolongada que contiene venlafaxina
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
AR032387A1 (es) Dentifrico con doble compuesto para la reduccion del mal aliento
PE20000329A1 (es) Derivados de indol y composiciones farmaceuticas que los contienen
ES2117474T3 (es) Derivados n-sustituidos del 4-hidroxiindol y composiciones de tinte de fibras queratinicas que los contienen.
AR016824A1 (es) Composiciones solidas o semisolidas de uso oral, que contienen calcio y un acidulante; procedimiento para prerarar dichas composiciones; uso de compuestosde calcio como inhbidores de la erosion dental
ES543139A0 (es) Un procedimiento para la preparacion de una composicion reparadora dental, que contiene un monomero de acrilato o metacrilato de bencilo monofuncional.
ES2176542T3 (es) Composicion de resina poliolefinica, y una pelicula laminada que la contiene.
ES2124069T3 (es) Compuestos heterociclicos aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
PE29798A1 (es) Acetidinas
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
ES2161292T3 (es) Composicion de higiene oral.
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
AR000490A1 (es) Una composición que absorbe humedad y un cable óptico que la comprende
AR001354A1 (es) Compuestos bi-aromaticos derivados de amida, composiciones farmacéuticas y cosméticas que los contien, y utilización de dichos compuestos y composición cosmética.
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
AR023511A1 (es) Composicion que comprende (s) y (r) 5-amino-3-ciano-1-(2,6-dicloro-4-trifluorometilfenil)-4-trifluoro-metilsulfinilpirazol, dichos compuestos aislados y usos de los mismos como plaguicida
ES2143833T3 (es) Acidos y esteres de la diosmetina y composiciones farmaceuticas que los contienen.
DE69003998D1 (de) N-Phenylamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel.

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term